Barclays PLC Has $157,000 Stake in INmune Bio, Inc. (NASDAQ:INMB)

Barclays PLC lifted its position in shares of INmune Bio, Inc. (NASDAQ:INMB) by 601.9% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 29,044 shares of the company’s stock after purchasing an additional 24,906 shares during the quarter. Barclays PLC’s holdings in INmune Bio were worth $157,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Financial Advocates Investment Management lifted its stake in INmune Bio by 17.4% in the 3rd quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after acquiring an additional 2,000 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of INmune Bio in the second quarter valued at approximately $121,000. Jane Street Group LLC bought a new stake in shares of INmune Bio in the third quarter worth $79,000. Fermata Advisors LLC boosted its holdings in INmune Bio by 25.2% during the third quarter. Fermata Advisors LLC now owns 42,730 shares of the company’s stock worth $230,000 after purchasing an additional 8,590 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in INmune Bio in the third quarter valued at $249,000. 12.72% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on INMB shares. Raymond James began coverage on shares of INmune Bio in a research report on Friday, September 27th. They set an “outperform” rating and a $18.00 price target on the stock. Alliance Global Partners started coverage on INmune Bio in a report on Monday, October 21st. They set a “buy” rating and a $20.00 target price on the stock.

INmune Bio Trading Up 3.0 %

Shares of INMB opened at $5.57 on Wednesday. The company has a market cap of $123.50 million, a price-to-earnings ratio of -2.56 and a beta of 1.78. The company’s fifty day simple moving average is $5.17 and its 200 day simple moving average is $6.20. INmune Bio, Inc. has a 1-year low of $4.32 and a 1-year high of $14.74.

INmune Bio (NASDAQ:INMB) last issued its earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 117.48%. During the same quarter in the prior year, the firm earned ($0.48) earnings per share. As a group, research analysts forecast that INmune Bio, Inc. will post -2.24 earnings per share for the current year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.